Mechanistic studies suggest that increased miR-802 expression may affect insulin sensitivity and glucose metabolism via the PI3K/AKT pathway, whereas the hepatic energy metabolism pathway (FXR/SHP/miR-802) may provide a novel target for T2D and NAFLD treatment [83]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.